Oxidative stress in diabetes - circulating advanced glycation end products, lipid oxidation and vascular disease

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 125-127

  Dias, Irundika H K ^a   Griffiths, Helen R ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPID METABOLISM; OXIDATION-REDUCTION; OXIDATIVE STRESS; VASCULAR DISEASES;

EID: 84898676781     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213508747     Document Type: Editorial

References (19)

1. Zannad F,Stough WG,Pocock SJ, et al.Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?.Eur Heart J. 2012;33:1049-1057.
2. Wolff SP,Dean RT.Glucose autooxidation and protein modification. The potential role of 'autooxidative glycosylation' in diabetes.Biochem J. 1987;245:243-250.
3. Ceriello A,Giugliano D,Quatraro A, et al.Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications?.Diabetes Care. 1991;14:68-72.
4. Giacco F,Brownlee M.Oxidative stress and diabetic complications.Circ Res. 2010;107:1058-1070.
5. Akbar S,Bellary S,Griffiths HR.Dietary antioxidant interventions in type 2 diabetes patients: a meta-analysis.Br J Diab Vas Dis. 2011;11:62-66.
6. Knott HM,Brown BE,Davies MJ, et al.Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes.Eur J Biochem. 2003;270:3572-3582.
7. Kassab A,Ajmi T,Issaoui M, et al.Homocysteine enhances LDL fatty acid peroxidation, promoting microalbuminuria in type 2 diabetes.Ann Clin Biochem. 2008;45:476-480.
8. Galan BE,Zoungas S,Chalmers J, et al.Cognitive function and risks of cardiovascular disease and hyperglycemia in patients with type 2 diabetes: the Action in Diabetes and Vascular disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial.Diabetologia. 2009;52:2328-2336.
9. Ahmed N,Thornalley PJ.Advanced glycation endproducts: what is their relevance to diabetic complications?.Diab Obesity Metab. 2007;9:233-245.
10. Li L,Willets RS,Polidori MC, et al.Oxidative LDL modification is increased in vascular dementia and is inversely associated with cognitive performance.Free Radic Res. 2010;44:241-248.
11. Polidori MC,Griffiths HR,Mariani E, et al.Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease.Amino Acids. 2007;32:553-559.
12. Lovell MA,Ehmann WD,Mattson MP, et al.Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease.Neurobiol Aging. 1997;18:457-461.
13. Skoumalová A,Ivica J,Santorová P, et al.The lipid peroxidation products as possible markers of Alzheimer's disease in blood.Exp Gerontol. 2010;46:38-42.
14. Goodarzi MT,Navidi AA,Rezaei M, et al.Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes.J Clin Lab Anal. 2010;24:72-76.
15. Toma L,Stancu CS,Botez GM, et al.Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose.Biochem Biophys Res Commun. 2009;390:877-882.
16. Palinski W,Rosenfeld ME,Ylä-Herttuala S, et al.Low density lipoprotein undergoes oxidative modification in vivo.Proc Natl Acad Sci U S A. 1989;86:1372-1376.
17. Smith KA,Shepherd J,Wakil A, et al.A comparison of methods for the measurement of 8-isoPGF2α: a marker of oxidative stress.Ann Clin Biochem. 2011;48:147-154.
18. Zhang Z-J.Systematic review on the association between F2-isoprostanes and cardiovascular disease.Ann Clin Biochem. 2013;50:108-114.
19. de la Monte SM,Wands JR.Alzheimer's disease is type 3 diabetes-evidence reviewed.J Diabetes Sci Technol. 2008;2:1101-1113.